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sFlt-1) traps circulating VEGF and is therefore anti-angiogenic. An 
emerging concept is that adenosine, known for its cardioprotective 
effects, is a major factor driving angiogenesis, thus contributing 
to the repair of the ischemic heart. The aims of the present study 
were (1) to characterize the effects of adenosine on VEGF and sFlt-
1, (2) to determine which subtype(s) of adenosine receptor (A1, 
A2a, A2b, A3) promote these effects.
Methods — Human primary cardiac  broblasts, myo broblasts, and 
blood monocyte-derived macrophages were treated with adenosine 
(10 m) or adenosine analogs, and/or LPS (100 ng/ml). In vitro 
formation of microtubules by human coronary artery cells (HCAEC) 
was used as an angiogenesis assay. Transgenic mice with cardiac-
speci c and inducible overexpression of A1 and A2a receptors were 
used. Wild type (WT) and A3 adenosine receptor knocked-out mice 
were subjected to transverse aortic constriction (TAC). ELISA, real-
time quantitative PCR,  ow cytometry and immunoblotting were 
used to measure levels of VEGF, HIF-1α and sFlt-1.
Results — Adenosine increased VEGF mRNA and protein expression 
by human primary  broblasts, myo broblasts and macrophages 
(22-fold increase in adenosine- and LPS-treated macrophages, 
P<0.0001). Up-regulation of VEGF by adenosine was replicated using 
agonists of A2a (C141) and A3 (IB-MECA) receptors, and inhibited by 
antagonists of A2a (SCH58261) and A2b (MRS1754) receptors. sFlt-1 
production induced by LPS was decreased by 43 % in the presence 
of adenosine (P=0.006). Adenosine enhanced the formation of a 
network of microtubules by HCAEC and this effect was dampened 
in the presence of VEGF-blocking antibody. Over-expression of 
the A2a receptor in mice enhanced VEGF and HIF-1α expression. 
TAC increased VEGF and HIF-1α expression in the heart, an effect 
inhibited in A3-de cient mice.
Conclusion — Adenosine plays a major role in angiogenesis through 
up-regulation of the pro-angiogenic VEGF and down-regulation 
of the anti-angiogenic sFlt-1. These effects appear to be mainly 
mediated by the A2a receptor. Our results suggest that both A2a 
and A3 receptors play signi cant roles in adenosine-mediated 
angiogenesis.
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Angiotensin II type 2 receptor (AT2R) stimulation is thought to 
induce vasodilation and apoptosis. Nevertheless, its role remains 
controversial. In hypertension and aging, AT2R might promote 
vasoconstriction and cell growth. In cancer cells, AT2R is highly 
expressed but its role remains poorly understood. Thus, we 
investigated the role of AT2R in tumor growth, hypothesizing that 
AT2R affects cell proliferation and/or tumor vascularization.
Tumor induction by 3-methylcholanthrene was signi cantly delayed 
in AT2R knockout mice, suggesting a role for AT2R in tumor initiation. 
Tumor growth after subcutaneous injection of LL/2 cancer cells in 
C57/BL6 mice treated with PD123,319, an AT2R antagonist, was 
decreased when PD123,319 was given at an early stage, suggesting 
that AT2R is also involved in tumor promotion. In vitro proliferation 
of LL/2 cells was reduced by PD123,319 with a signi cant decrease 
in Ki67 expression and ERK1/2 phosphorylation. In addition, tumor 
vascular density, measured by CD31 labeling and angiogenesis using 
the aortic ring assay on Matrigel®, were reduced by PD123,319 and 
in AT2R-null mice. Therefore, we uncovered a novel mechanism by 
which AT2R promotes tumor development favoring both malignant 
cancer cell proliferation and tumor angiogenesis. Thus, blocking 
AT2R could be a new approach in tumor therapy.
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Increased permeability of, and bleeding from, microvessels within 
the atheromatous arterial wall participate in atherothrombosis 
progression. The VEGF family and angiopoietin system components 
govern microvessel development and maturation. Serine protease 
activities are proportional to atherothrombosis progression and 
linked to intraplaque hemorrhage. Here we investigated the 
relationship between angiogenic factors and proteases in human 
hemorrhagic and non-hemorrhagic atheromatous carotid samples 
by immunohistochemistry, in situ hybridization and ELISA. 
Plaque activity of plasmin and leukocyte elastase and proteolysis 
of angiogenic factors by plaque extracts were determined. 
Smooth muscle cell migration induced by hemorrhagic and non-
hemorrhagic plaques was assessed. The absence of á-actin-positive 
cells characterized microvessels in hemorrhagic areas in spite of 
similar expression of VEGF and angiopoietin system components in 
microvessels of hemorrhagic and non-hemorrhagic areas. However, 
VEGF, PlGF and angiopoietin-1 levels were signi cantly decreased 
in hemorrhagic compared to non-hemorrhagic plaques, whereas 
angiopoietin-2 did not change and soluble Tie-2 levels increased. 
Consequently, smooth muscle cell migration stimulatory activity of 
hemorrhagic plaques was reduced. Recombinant PlGF, VEGF and 
angiopoietin-1 added to plaque extracts were only degraded by 
hemorrhagic lesions. This proteolysis was prevented by inhibitors of 
plasmin and elastase, whose activity was increased in hemorrhagic 
plaques. No degradation was observed for angiopoietin-2. Decreased 
angiogenic factor levels caused by proteolysis may destabilize 
plaque microvessels via impairment of mural cell recruitment, thus 
leading to a vicious circle of intraplaque hemorrhages and lesion 
progression.
